Every 10-Q that CV SCIENCES INC (CVSI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CVSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVSI filings page.
CV Sciences, Inc. reported weaker results for the quarter and six months ended June 30, 2026. Net product sales were $2.99 million in Q2 2026, down 17.5% from $3.62 million, and $6.18 million for the first half, down 14.5%. The decline reflected lower unit volumes driven by restrictive state regulations, out-of-stock issues, and reduced third‑party contract manufacturing revenue, partially offset by contributions from newer products.
Gross margin remained roughly stable at 48.6% in Q2 (50.9% a year earlier). The company recorded a Q2 net loss of $0.78 million and a six‑month net loss of $1.42 million; Adjusted EBITDA was negative in both periods. Cash was only $0.27 million with a small working capital deficit and an accumulated deficit of $89.4 million, and management disclosed substantial doubt about the ability to continue as a going concern, expecting reliance on additional capital and continued cost reductions.
During 2026, a secured promissory note was amended into convertible notes, measured at fair value with a $1.02 million liability at June 30, and 28.9 million shares were issued on conversions in the first half, increasing shares outstanding to 213.1 million (225.8 million by August 11). New U.S. legislation (the 2026 Act) will limit hemp‑derived consumable products to 0.4 mg total THC per container; the company is assessing formulation and compliance changes and states this could materially adversely affect its business.
CV Sciences, Inc. reported Q3 results marked by softer sales and tight liquidity while taking steps to refinance debt and reduce obligations. Product sales, net were $3.256M versus $3.865M a year ago. Gross profit was $1.579M, and the company posted a net loss of $382K compared to a loss of $456K in Q3 2024.
Cash was $381K as of September 30, 2025, with operating cash use of $53K year‑to‑date. Total assets were $6.995M and stockholders’ equity was $1.539M. The company amended a $1.6M secured note in September 2025 and paid the investor $150K; it also fully repaid a prior Streeterville note, recognizing a $37.5K gain. Subsequent to quarter‑end, it issued a new secured note with original principal of $600K for net proceeds of $300K.
Management disclosed substantial doubt about continuing as a going concern and noted new federal legislation effective November 13, 2026 that will prohibit sales of hemp‑derived products containing more than 0.4 milligrams of total THC per container, which the company is evaluating. Shares outstanding were 184,263,663 as of November 11, 2025.